



HESI THRIVE

Innovating Translational Research • Improving Quality of Life After Cancer

www.hesithrive.org



MISSION

The THRIVE program seeks to chart new futures for cancer patients and survivors by making patient quality of life an active research priority.

WHY THRIVE?

THRIVE is a first of its kind initiative that fills a critical gap in funding for foundational research in support of future protective therapies, mitigation strategies, and a next generation of drugs that will enhance the ability for cancer patients and survivors to thrive. THRIVE is uniquely positioned for success, as the program gains input from a broad range of stakeholders and experts. THRIVE's seed grant program and outreach initiatives aim to raise the visibility of the need and to support the development of innovative solutions that improve patient quality of life.


HOW CAN I SUPPORT THRIVE?

1. Help us to raise awareness and build connections.
2. Participate in the 2018 HESI THRIVE partners meeting
3. Support our research efforts by donating at www.hesithrive.org

ABOUT HESI

HESI is a nonprofit 501(c)(3) organization that brings together scientists from academia, government, industry, and NGOs from around the world to ensure the health and safety of people and our environment. Learn more at www.hesiglobal.org

ACCOMPLISHMENTS



February 2016

THRIVE begins with a seed grant program focused on improving quality of life for cancer patients and survivors

June 2016

THRIVE Advisory Board publishes perspective in Science Translational Medicine

October 2016

Former Vice President Joe Biden names HESI as a partner for the White House Cancer Moonshot Task Force

December 2016

Inaugural HESI THRIVE grantees are announced

January 2017-January 2018:

Research and outreach underway

Early 2018

First THRIVE partners meeting will occur

2017 GRANT RECIPIENTS

Irina Budunova, MD, PHD.
Leo Gordon, MD, FACP
Northwestern University
Feinberg School of
Medicine



Evaluating co-therapies that may reduce atrophic and metabolic side effects of glucocorticoids in patients with blood cancers (e.g., leukemia, lymphoma, and myeloma)

Maria Suarez-Almazor, MD, PhD
Chief Section of Rheumatology
and Clinical Immunology
MD Anderson Cancer Center



Defining the genetic profile of patients that experience adverse responses to immunotherapy to help inform future treatment selection

Barbara Ehrlich, PhD
Professor of Pharmacology
Yale University



Developing a nerve function test that can characterize breast cancer patients most likely to experience serious nerve injury from breast cancer treatment

Jennifer Jordan, PhD
Wake Forest University
School of Medicine
Assistant Professor,
Cardiovascular Medicine



Evaluating novel mechanisms of chronic heart damage with cardiac MRI in patients who have received anthracyclines

COLLABORATORS



ELSA U. PARDEE FOUNDATION

